ADMA Biologics, Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: ADMA Biologics, Inc. |
| Ticker: | Ticker: ADMA |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors,” had confirmed independently that “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.” On this news, the price of ADMA shares declined by $2.26 per share, or approximately 17%, from $13.59 per share on March 23, 2026 to close at $11.33 on March 24, 2026.
On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors,” had confirmed independently that “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.” On this news, the price of ADMA shares declined by $2.26 per share, or approximately 17%, from $13.59 per share on March 23, 2026 to close at $11.33 on March 24, 2026.